demonstrates not only that biocatalysts can be of sufficient quality to carry out useful photochemistry, but that in some ways they may be more advantageous in biological applications. Most traditional nanoparticle syntheses require organic capping ligands to control the particle shape. These ligands present a barrier to charge transfer between the semiconductor and the catalyst, often requiring electron tunneling (13). The ligand-free approach taken here may help to establish a favorable interface between the bacteria and the semiconductor, resulting in improved efficiencies. Additionally, metal catalysts such as CdS have had limited application because of oxidative photodegradation; the ability of bacteria to precipitate metal chloroacides from the products of photodissolution (Cd2+ and oxidized sulfur complex ions) suggests a potential regenerative pathway to circumvent the debilitating photoinstability through a self-regenerative process. The M. thermoacetica–CdS system displays behavior that may help it to exceed the utility of natural photosynthesis. First, the quantum yield increased with higher M. thermoacetica–CdS concentrations. The ability to tune the effective light flux per bacterium by changing the concentration of the suspension is a considerable advantage over similar light management practices in natural photosynthesis that are achieved through genetic engineering of chloroplast expression (28). Second, the catalytic energy loss observed during dark cycles in natural photosynthesis was absent in our hybrid system, which may be an innate feature of the Wood-Ljungdahl pathway, in which acetic acid is a waste product of normal respiration. Additionally, many plants and algae tend to store a large portion of their photosynthetic products as biomass, which requires extensive processing to produce useful chemicals. In contrast, the M. thermoacetica–CdS system directs ~90% of photosynthetic products toward acetic acid, reducing the cost of diversifying to other chemical products. This system could be improved by substituting Cys oxidation with a more beneficial oxidation reaction, such as oxygen evolution, wastewater oxidation for water purification, or oxidative biotransformation, into the human population. For example, the forage of normal respiration. Addi-

**REFERENCES AND NOTES**

19. Materials and methods are available as supplementary materials on Science Online.

**ACKNOWLEDGMENTS**

The interface design part of this work was supported by the U.S. Department of Energy under contract no. DE-AC02-05CH11231 (PChem). Work at the Molecular Foundry was supported by the Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under contract no. DE-AC02-05CH11231. Solar-to-chemical production experiments were supported by NSF (grant DMR-1507914). The authors thank J. J. Gallagher and M. C. Y. Chang for the original inoculum of M. thermoacetica ATPC 38703. KXS acknowledges support from the NSF Graduate Research Fellowship Program under grant DGE-1106400. The authors thank the National Center for Electron Microscopy. All data are available in the body of the paper or in the supplementary materials.

**SUPPLEMENTARY MATERIALS**

www.sciencemag.org/content/351/6268/74/suppl/DC1

8 Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.

**VIROLOGY**

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

Bart L. Haagmans,1* Judith M. A. van den Brand,1 Y. Stalin Raj,1 Asisa Volz,2 Peter Wohlsein,3 Saskia L. Smits,1 Debby Schipper,1 Theo M. Bestebroer,1 Nisreen Okba,1 Robert Fux,2 Albert Bensaid,4 David Solanes Foz,3 Thijs Kuiken,1 Wolfgang Baumgartner,1 Joaquim Segalés,4,6 Gerd Sutter,2,6 Albert D. M. E. Osterhaus1,7,8

Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.

**Coronaviruses (CoVs)** cause common colds in humans, but zoonotic transmissions occasionally introduce more pathogenic viruses into the human population. For example, the SARS-CoV caused the 2003 outbreak of severe acute respiratory syndrome (SARS). In 2012, a previously unknown virus, now named Middle East respiratory syndrome CoV (MERS-CoV), was isolated from the sputum of a 60-year-old Saudi Arabian man who suffered from acute pneumonia and subsequently died (1, 2). Several infection clusters have been reported over the past
Fig. 1. Virus-neutralizing antibody responses to MERS-CoV, MVA, and camelpox virus in vaccinated dromedary camels. (A to D) Individual virus neutralization titers (VNT) from dromedary camels vaccinated with PBS, MVA-wt, or MVA-S against MERS-CoV [(A) and (B)], MVA (C), and camelpox virus (D), as determined from sera [(A), (C), and (D)] and nasal swabs (B). Here, VNT is expressed as the ratio denominator only [i.e., 32 on the y axis of (A) represents 1:32]. Different symbols indicate time points after immunization sera were analyzed: week 0 (black circles), week 4 (blue triangles), and week 7 (red squares). Dashed lines depict the detection limit of the assays.

As the MERS-CoV receptor (17) has facilitated the subsequent characterization of the receptor binding domain in the S1 region of the MERS-CoV spike protein (18, 19). When tested as a vaccine in mice, full-length spike protein of MERS-CoV expressed by modified vaccinia virus Ankara (MVA-S) induced high levels of circulating antibodies that neutralize MERS-CoV and limited lower respiratory tract replication in animals transduced with the human receptor DPP4 and inoculated with MERS-CoV (20, 21). MVA, a highly attenuated strain of vaccinia virus, serves as one of the most advanced recombinant poxvirus vectors in preclinical and clinical trials for vaccines against infectious diseases and cancer. As a proof of principle, we tested the protective efficacy of a MVA–MERS-CoV candidate vaccine in dromedary camels.

In dromedary camels, MERS-CoV replication is mainly restricted to the upper respiratory tract (22). Therefore, we inoculated four dromedary camels twice at a 4-week interval, with 2 × 10³ plaque-forming units (PFU) MVA-S administered in both nostrils via a mucosal atomization device, to disperse the virus on the nasal epithelium, and 10³ PFU MVA-S delivered intramuscularly in the neck of each animal (23). Similarly, four control animals received nonrecombinant wild-type MVA (MVA-wt) (n = 2) or phosphate-buffered saline (PBS) (n = 2). All animals vaccinated with the MVA-S vaccine developed detectable serum neutralizing MERS-CoV–specific antibody titers (Fig. 1A). No MERS-CoV–specific antibodies were detected in sera of the PBS- or MVA-wt–immunized control animals. The specificity of the antibody response was confirmed by enzyme-linked immunosorbent assay, using recombinant S1 protein (fig. S1). In addition, low levels of MERS-CoV–neutralizing antibodies (virus neutralization titer of 1:20 to 1:40) were detected 3 weeks after the boost immunization in the nasal swabs of three animals (Fig. 1B). Because a MVA-vectored vaccine was used, antibodies neutralizing MVA were also detected (Fig. 1C); these antibodies cross-neutralized camelpox virus (Fig. 1D).

Three weeks after the boost immunization, all dromedary camels were inoculated with 10³ median tissue culture infectious dose (TCID₅₀) of MERS-CoV via the intranasal route, using a mucosal atomization device. Upon challenge, the animals showed only mild clinical signs, which were mainly limited to a relatively small rise in body temperature in control-vaccinated animals 1 day after challenge (fig. S2). In addition, some dry mucus was observed in one of the nostrils of most animals after day 4, but from days 8 to 10 onward, all control-vaccinated animals exhibited a runny nose that was not observed in MVA-S–vaccinated animals (Fig. 2, A and B). Previous studies have shown that both experimentally and naturally infected dromedary camels may show nasal discharge after MERS-CoV infection (15, 22). We next tested nasal respiratory tract samples for the presence of infectious virus. Whereas MERS-CoV was found at high titers in all four control-vaccinated animals, mean viral titers in the animals that received the MVA-S vaccine were significantly reduced (Fig. 2C). At 4 days post-inoculation (dpi), an increase in MERS-CoV RNA level was noted in the MVA-S–vaccinated animals (Fig. 2D). At 6 dpi, one of the MVA-S–vaccinated animals excreted low levels of infectious virus (10³ TCID₅₀/ml) (Fig. 2C). Sequencing of the spike gene of this virus showed no amino acid changes in the receptor binding domain (fig. S3), which suggests that this virus did not emerge as
Fig. 2. Clinical signs and MERS-CoV excretion in nasal swabs of dromedary camels vaccinated with MVA-S vaccine. (A and B) Two MVA-S–vaccinated (A) and two control-vaccinated dromedary camels (B) were analyzed for the presence of mucus excretion 8 to 10 days after MERS-CoV challenge. (C and D) Detection of infectious MERS-CoV (C) and MERS-CoV RNA (D) at different time points after challenge in nasal swabs of dromedary camels vaccinated with MVA-S (white bars) or MVA-wt or PBS (black bars). Dashed lines depict the detection limit of the assays. Error bars represent mean values ± SEM; *P < 0.05; n = 4 animals per group. GE, genome equivalents.

Fig. 3. Detection of MERS-CoV in tissues of vaccinated dromedary camels. (A and B) Levels of MERS-CoV viral RNA (A) and infectious virus (B) were determined in tissue homogenates from MVA-S–vaccinated (green and black bars) or control-vaccinated (red and blue bars) camels 4 days after challenge.
a result of escape from vaccine-induced antibodies (Fig. 2C). Rather, the observation that this animal had no detectable MERS-CoV antibody response in the nasal swab at time of challenge may indicate that, for unknown reasons, priming with the MVA-S vaccine was less effective in this animal compared with the other vaccinated animals. Antibodies to MERS-CoV rapidly increased 8 dpi in control-vaccinated animals (fig. S4), consistent with the absence of infectious virus in the nasal swabs at that time (Fig. 2C). Low levels of viral RNA, but no infectious virus, were detected in control swabs after MERS-CoV challenge (fig. S5), but not in any of the sera tested.

To analyze pathological changes and viral replication in organs of the animals, we euthanized two animals per group and performed necropsies at 4 and 14 dpi. Gross pathology showed no substantial changes in the organs of any of the animals. However, at 4 dpi MERS-CoV RNA transcripts were detected in several organs of the control-vaccinated animals (Fig. 3A), although infectious virus particles were restricted to noses and tracheas (Fig. 3B). In the absence of infectious MERS-CoV, relatively high levels of viral RNA have also been observed in tissues of experimentally infected rhesus macaques and rabbits (25, 26). In contrast, infectious MERS-CoV particles were found at low levels in the noses of animals that had received the MVA-S vaccine (Fig. 3B). At 14 dpi, only viral RNA was detected, mainly in control-vaccinated animals (fig. S6).

Differences in upper respiratory tract viral replication between vaccinated groups were confirmed by MERS-CoV in situ hybridization (ISH) and immunohistochemistry (IHC). At 4 dpi, only a few cells in the nasal epithelium of MVA-S-vaccinated dromedaries stained positive for MERS-CoV RNA by ISH, as compared with cells from control-vaccinated animals (Fig. 4, A and B). Viral replication in the control-vaccinated animals was consistent with histopathological analyses showing multifocal moderate rhinitis with multifocal epithelial necrosis, as well as lymphocytic and neutrophilic exocytosis (Fig. 4C). In the nasal submucosa, we observed edema and infiltrates with lymphocytes, neutrophils, plasma cells, and macrophages. In the trachea and bronchi, we noted infiltration in the lamina propria, as well as a multifocal mild tracheitis and bronchitis with epithelial necrosis and lymphocytic and neutrophilic exocytosis. In the lymph nodes and the tonsils, we detected follicular hyperplasia. Marked MERS-CoV antigen expression in the nasal epithelium was associated with the nasal lesions (Fig. 4C). Through the use of ISH, the presence of MERS-CoV RNA in the nasal cavity was confirmed in cells similar to those that scored positive by IHC (Fig. 4C). Furthermore, a few epithelial cells in the trachea and bronchi and those covering the palatum molle—as well as large stellate cells (consistent with dendritic cells) in the lymphoid tissue of the palatum molle, tonsils, and tracheal and cervical lymph nodes—were found to be positive for viral antigen by IHC (fig. S7). In contrast, in MVA-S-vaccinated animals the rhinitis was accompanied by less submucosal edema with antigen expression in some nasal cells (Fig. 4C). Eosinophilic granulocytes were not observed in the lungs of MVA-S-vaccinated animals challenged with MERS-CoV. In one MVA-S-vaccinated animal, viral antigen expression was found in a few dendritic-like cells in the lymphoid tissue of the palatum molle, tonsils, and tracheal and cervical lymph nodes, as well as in the gut-associated lymphoid tissue of the duodenum (table S1). At 14 dpi, we observed multifocal mild rhinitis, tracheitis, and bronchitis and follicular hyperplasia in the lymphoid tissue of control- and MVA-S-vaccinated animals. In the lungs of almost all animals, we detected multifocal mild infiltration of neutrophils, histiocytes, and lymphocytes that was not associated with viral antigen expression. In the other extrarespiratory tissues examined, we found no substantial morphological changes or viral antigen expression. Overall, these results indicate that vaccination of dromedary camels with MVA-S induces protective immunity resulting in reduction of excreted infectious MERS-CoV, without evidence for antibody-dependent enhancement of viral replication, as seen in feline CoV infection (27). Given the potential transient nature of mucosal immune responses, follow-up studies are needed to determine the longevity of the responses induced by the MVA-S vaccine, with respect to protection as well as antibody-dependent enhancement of viral replication when antibody levels are waning. In addition, dosing of the vaccine and alternative methods of administration must be explored in more detail before this candidate vaccine will be useful in the field.

Protective immunity to CoVs is orchestrated by antibody and cellular immune responses. Investigations in mice have already provided evidence that inoculation with MERS-CoV spike protein-based candidate vaccines, monoclonal antibodies directed against the spike protein, or dromedary immune serum induces protective immunity against lower respiratory tract MERS-CoV infection (28-30). In dromedary camels, a DNA vaccine encoding the spike protein induced MERS-CoV neutralizing antibody responses that were similar to antibody levels in animals inoculated with the MVA-S vaccine, but no challenge experiments were performed (31). However, studies in the field also indicated that MERS-CoV-seropositive dromedaries may carry MERS-CoV viral RNA in their nasal excretions (8, 15, 16). Thus, sterilizing immunity...
Outbreaks of Middle East respiratory syndrome (MERS) raise questions about the prevalence and evolution of the MERS coronavirus (CoV) in its animal reservoir. Our surveillance in Saudi Arabia in 2014 and 2015 showed that viruses of the MERS-CoV species and a human CoV 229E-related lineage co-circulated at high prevalence, with frequent co-infections in the upper respiratory tract of dromedary camels. Including a betacoronavirus 1 species, we found that dromedary camels share three CoV species with humans. Several MERS-CoV lineages were present in camels, including a recombinant lineage that has been dominant since December 2014 and that is subsequently linked to the human outbreaks in 2015. Camels therefore serve as an important reservoir for the maintenance and diversification of the MERS-CoVs and are the source of human infections with this virus.

S1 and S2), only nasal swabs were subsequently collected from camels at slaughterhouses, farms, and control animal facilities for technical assistance. This study was funded by Nederlandse Organisatie voor Wetenschappelijk Onderzoek (grant 91213056) and was supported in part by the Niedersachsen-Research Network on Neuroinfectiology (N-RENT) of the Ministry of Science and Culture of Lower Saxony, Germany. Animal model development was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI project) [Innovative Medicines Initiative (IMI) grant 115760], with assistance and financial support from IMI and the European Commission and contributions from the EFPIA partners. B.L.H., V.S.R., T.M.B., G.S., and A.D.M.E.O. have applied for patents on MERS-CoV. A.D.M.E.O. is chief scientific officer of Viroclinics Biosciences. A.D.M.E.O. and T.K. hold certificates of shares in Viroclinics Biosciences. Nucleotide sequence data are available in GenBank under accession numbers KT966879 and KT966880.

**SUPPLEMENTARY MATERIALS**

www.sciencemag.org/content/351/6268/77/suppl/DC1

Materials and Methods

Figs. S1 to S7

Table S1

References (34–35)

31 July 2015; accepted 12 November 2015

Published online 17 December 2015

10.1126/science.aad283

VIROLOGY

Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia

Jamal S. M. Sabir,1* Tommy T.-Y. Lam,2,3,4,5 Mohamed M. M. Ahmed,1,6,7 Lifeng Li,3,8 Yongyi Shen,1,3,4 Salah E. M. Abo-Aba,1,7 Muhammad I. Qureshi,1 Mohamed Abu-Zeid,1,7 Yu Zhang,1,3,8 Mohammad A. Khilyami,4 Njed S. Alharbi,1,7,8 Nahid H. Hajrah,5,8 Meeshaal J. Sabir,1,7,8,9,10 Mohammed H. Z. Mutwakil,1,8,9 Saleh A. Kabli,1,8,9 Faten A. S. Alsalaimany,1,8 Abdullah Y. Obaid,1,8 Boping Zhou,2,3,4 David K. Smith,1,8 Edward C. Holmes,1,8 Huachen Zhu,2,3,4,5 Yi Guan1,3,4,5

Outbreaks of Middle East respiratory syndrome (MERS) raise questions about the prevalence and evolution of the MERS-CoV (CoV) in its animal reservoir. Our surveillance in Saudi Arabia in 2014 and 2015 showed that viruses of the MERS-CoV species and a human CoV 229E-related lineage co-circulated at high prevalence, with frequent co-infections in the upper respiratory tract of dromedary camels. Including a betacoronavirus 1 species, we found that dromedary camels share three CoV species with humans. Several MERS-CoV lineages were present in camels, including a recombinant lineage that has been dominant since December 2014 and that is subsequently linked to the human outbreaks in 2015. Camels therefore serve as an important reservoir for the maintenance and diversification of the MERS-CoVs and are the source of human infections with this virus.

Major outbreaks of Middle East respiratory syndrome (MERS) have been repeatedly reported in the Arabian Peninsula since 2012 and recently in South Korea (1–3), renewing concerns about potential changes in the mode of MERS coronavirus (CoV) transmission. Although increasing evidence suggests that dromedary camels are the most likely source of human infections (4–14), the prevalence and evolution of the MERS-CoV in this animal and the route of virus transmission to humans are not well defined, and little is known of other CoV species that may circulate in camels and how they might influence CoV ecology.

We conducted surveillance for CoVs in dromedary camels in Saudi Arabia, the country most affected by MERS, from May 2014 to April 2015. Initially, paired nasal and rectal swabs were collected from camels at slaughterhouses, farms, and wholesale markets in Jeddah and Riyadh. Because rectal swabs were negative for MERS-CoVs (tables S1 and S2), only nasal swabs were subsequently collected at these sites and in Taif (15). Of the 1309 camels tested, 25.3% were positive for CoV, as established by reverse transcription polymerase chain reaction (RT-PCR) and confirmed by Sanger sequencing. The majority of the CoV-positive camels

1Biotechnology Research Group, Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.2State Key Laboratory of Emerging Infectious Diseases (The University of Hong Kong–Sherenzhen Branch), Shenzhen Third People’s Hospital, Shenzhen, China.3Centre of Influenza Research and State Key Laboratory of Emerging Infectious Diseases, School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China.4Mieh Barch Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Biological Sciences and Sydney Medical School, The University of Sydney, Sydney, New South Wales 2006, Australia.5Department of Nutric Acid Research, Genetic Engineering and Biotechnology Research Institute, City for Scientific Research and Technology Applications, Borg El Arab, Post Office Box 21934, Alexandria, Egypt.6Microbial Genetics Department, Genetic Engineering and Biotechnology Division, National Research Center, Dokki, Giza, Egypt.7King Abdulaziz City for Science and Technology, Riyadh 11442, Saudi Arabia.8Department of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.†These authors contributed equally to this work.‡Corresponding author. E-mail: zuhachl@hkbu.hk (H.Z.); yguan@hkbu.hk (Y.G.)
An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
Science 351 (6268), 77-81. [doi: 10.1126/science.aad1283] originally published online December 17, 2015

Editor's Summary

Coronaviruses in the Middle East

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe acute respiratory illness and kills about a third of people infected. The virus is common in dromedary camels, which can be a source of human infections. In a survey for MERSCoV in over 1300 Saudi Arabian camels, Sabir et al. found that dromedaries share three coronavirus species with humans. Diverse MERS lineages in camels have caused human infections, which suggests that transfer among host species occurs quite easily. Haagmans et al. made a MERS-CoV vaccine for use in camels, using poxvirus as a vehicle. The vaccine significantly reduced virus excretion, which should help reduce the potential for transmission to humans, and conferred cross-immunity to camelpox infections.

Science, this issue p. 81, p. 77